These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38979828)

  • 1. Improvement of medication adherence for desmopressin by adjusting the prescription dosage in male patients with overactive bladder: A claims database analysis.
    Tsubouchi K; Maeda T; Emoto T; Aoyagi C; Matsuoka W; Yamazaki F; Nakagawa C; Fukuhara Y; Tominaga K; Gunge N; Miyazaki T; Okabe Y; Matsuzaki H; Nakamura N; Arima H; Haga N
    Neurourol Urodyn; 2024 Jul; ():. PubMed ID: 38979828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.
    Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
    Adv Ther; 2024 May; 41(5):2086-2097. PubMed ID: 38520502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing adherence and persistence across 6 chronic medication classes.
    Yeaw J; Benner JS; Walt JG; Sian S; Smith DB
    J Manag Care Pharm; 2009; 15(9):728-40. PubMed ID: 19954264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [INITIAL TREATMENT OF NOCTURIA CAUSED BY NOCTURNAL POLYURIA WITH LOW-DOSE DESMOPRESSIN].
    Hayashi K; Fuji K; Omizu M; Hiramatsu A; Koizumi S; Matsubara E; Saito K; Yamagishi M; Sasaki H; Fukagai T; Ishikawa K; Ogawa Y
    Nihon Hinyokika Gakkai Zasshi; 2021; 112(1):18-24. PubMed ID: 35046231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study.
    Rovner ES; Raymond K; Andruczyk E; Juul KV
    Low Urin Tract Symptoms; 2018 Sep; 10(3):221-230. PubMed ID: 28560762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
    D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
    J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety of desmopressin orally disintegrating tablets in men with nocturia due to nocturnal polyuria: Interim results of a specified drug use-results survey in Japan.
    Ogawa Y; Murata S; Kuramoto K; Nakano A
    Low Urin Tract Symptoms; 2024 May; 16(3):e12513. PubMed ID: 38616722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of Effect Predictors of Desmopressin in Nocturia Patients With Nocturnal Polyuria.
    Kurose H; Ogasawara N; Ueda K; Chikui K; Uemura K; Nishihara K; Nakiri M; Suekane S; Igawa T
    In Vivo; 2023; 37(6):2726-2733. PubMed ID: 37905667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Danish population-based cohort study of desmopressin use in adults with nocturia or nocturnal enuresis.
    Juul KV; Schrøder MK; Mahler B; Rittig S; Nørgaard JP
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O121-O126. PubMed ID: 29992760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining the optimal initial dose for Japanese patients with nocturnal polyuria using an initial dose of desmopressin 50 μg.
    Kurose H; Komiya K; Ogasawara N; Ueda K; Chikui K; Nishihara K; Nakiri M; Matsuo M; Suekane S; Igawa T
    Low Urin Tract Symptoms; 2023 May; 15(3):89-95. PubMed ID: 36755502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study.
    Sand PK; Dmochowski RR; Reddy J; van der Meulen EA
    J Urol; 2013 Sep; 190(3):958-64. PubMed ID: 23454404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of desmopressin on frequency and urgency in female patients with overactive bladder and nocturia, current clinical features and outcomes: A systematic review.
    Barakat B; Franke K; May M; Gauger U; Vögeli TA
    Asian J Urol; 2022 Jan; 9(1):27-34. PubMed ID: 35198394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program.
    Yamaguchi O; Juul KV; Falahati A; Yoshimura T; Imura F; Kitamura M
    Low Urin Tract Symptoms; 2020 Jan; 12(1):8-19. PubMed ID: 31397969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of desmopressin orally disintegrating tablets 25 and 50 μg in male patients with nocturia: A Japanese real-world multicenter clinical study.
    Kyoda Y; Kimura M; Shimizu T; Miyao N; Ogasawara T; Shimizu T; Iwasawa A; Yorozuya W; Hashimoto J; Ichihara K; Takei F; Uchida K; Kouzen N; Suzuki N; Tachikawa K; Shibuya A; Muranaka I; Okada M; Igarashi M; Shibamori K; Nofuji S; Fujino K; Toyota T; Ito Y; Shinkai N; Hashimoto K; Kobayashi K; Tanaka T; Masumori N
    Low Urin Tract Symptoms; 2022 Nov; 14(6):410-415. PubMed ID: 36319193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [EFFICACY AND SAFETY OF INITIAL DESMOPRESSIN DOSE OF 50 μg IN ELDERLY MALE PATIENTS WITH NOCTURNAL POLYURIA].
    Kurose H; Komiya K; Ogasawara N; Ueda K; Chikui K; Nishihara K; Nakiri M; Matsuo M; Suekane S; Igawa T
    Nihon Hinyokika Gakkai Zasshi; 2022; 113(4):115-121. PubMed ID: 37866930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Patterns Associated with ACR-Recommended Medications in the Management of Fibromyalgia in the United States.
    Liu Y; Qian C; Yang M
    J Manag Care Spec Pharm; 2016 Mar; 22(3):263-71. PubMed ID: 27003556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A; Compion G; Fahey A; Siddiqui E
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial.
    Yamaguchi O; Nishizawa O; Juul KV; Nørgaard JP
    BJU Int; 2013 Mar; 111(3):474-84. PubMed ID: 23046147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desmopressin is an effective treatment for mixed nocturia with nocturnal polyuria and decreased nocturnal bladder capacity.
    Lee HW; Choo MS; Lee JG; Park CH; Paick JS; Lee JZ; Han DH; Park WH; Lee KS
    J Korean Med Sci; 2010 Dec; 25(12):1792-7. PubMed ID: 21165296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis.
    Kato D; Uno S; Van Schyndle J; Fan A; Kimura T
    Int J Urol; 2017 Oct; 24(10):757-764. PubMed ID: 28833621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.